Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
- Home
- Publications
- Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
Latest News
-
Prostate Cancer Survivor Stories That Inspire Hope
09 Jul, 2026 -
-
-
-
Seminar & Events
-
Baghdad clinic
30 Sep, 2024 -
Saudi German Hospital
26 Sep, 2024 -
Oncology Program
16 Sep, 2024 -
Oncology marketing
06 Sep, 2024 -
CAR-T THERAPY
14 Aug, 2024